Annual Report 2019

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2019 86 The United Laboratories International Holdings Limited Annual Report 2019 5. REVENUE AND SEGMENT INFORMATION The Group is currently organised into three revenue streams, including Intermediate products; Bulk medicine; and Finished products. (i) Disaggregation of revenue from contracts with customers For the year ended 31 December 2019 Intermediate Bulk Finished products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products 6-APA 876,272 – – 876,272 – 876,272 Antibiotics products – 3,592,613 2,146,648 5,739,261 – 5,739,261 Insulin Products – – 858,700 858,700 – 858,700 Others 404,080 499 513,788 918,367 – 918,367 Revenue from contracts with customers 1,280,352 3,593,112 3,519,136 8,392,600 – 8,392,600 Inter-segment sales 1,516,838 533,695 – 2,050,533 (2,050,533) – Segment revenue 2,797,190 4,126,807 3,519,136 10,443,133 (2,050,533) 8,392,600